X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare AJANTA PHARMA with IPCA Labs - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs IPCA LABS - Comparison Results

IPCA LABS 
   Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA IPCA LABS AJANTA PHARMA/
IPCA LABS
 
P/E (TTM) x 24.2 42.1 57.5% View Chart
P/BV x 10.0 3.2 309.0% View Chart
Dividend Yield % 0.6 0.2 378.0%  

Financials

 AJANTA PHARMA   IPCA LABS
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-16
IPCA LABS
Mar-17
AJANTA PHARMA/
IPCA LABS
5-Yr Chart
Click to enlarge
High Rs1,720643 267.5%   
Low Rs1,103503 219.4%   
Sales per share (Unadj.) Rs194.6254.4 76.5%  
Earnings per share (Unadj.) Rs45.216.1 281.4%  
Cash flow per share (Unadj.) Rs50.329.8 168.9%  
Dividends per share (Unadj.) Rs8.001.00 800.0%  
Dividend yield (eoy) %0.60.2 324.7%  
Book value per share (Unadj.) Rs132.0194.6 67.9%  
Shares outstanding (eoy) m88.77126.20 70.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x7.32.3 322.1%   
Avg P/E ratio x31.235.7 87.6%  
P/CF ratio (eoy) x28.119.2 145.9%  
Price / Book Value ratio x10.72.9 363.0%  
Dividend payout %17.76.2 284.3%   
Avg Mkt Cap Rs m125,29972,300 173.3%   
No. of employees `000NA13.3 0.0%   
Total wages/salary Rs m2,5706,960 36.9%   
Avg. sales/employee Rs ThNM2,413.5-  
Avg. wages/employee Rs ThNM523.2-  
Avg. net profit/employee Rs ThNM152.4-  
INCOME DATA
Net Sales Rs m17,27532,106 53.8%  
Other income Rs m166226 73.7%   
Total revenues Rs m17,44232,332 53.9%   
Gross profit Rs m5,8074,448 130.6%  
Depreciation Rs m4511,730 26.1%   
Interest Rs m49241 20.3%   
Profit before tax Rs m5,4742,703 202.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,460675 216.2%   
Profit after tax Rs m4,0142,028 197.9%  
Gross profit margin %33.613.9 242.7%  
Effective tax rate %26.725.0 106.8%   
Net profit margin %23.26.3 367.9%  
BALANCE SHEET DATA
Current assets Rs m7,63917,340 44.1%   
Current liabilities Rs m2,7159,559 28.4%   
Net working cap to sales %28.524.2 117.6%  
Current ratio x2.81.8 155.1%  
Inventory Days Days43100 43.1%  
Debtors Days Days7957 138.4%  
Net fixed assets Rs m6,91420,779 33.3%   
Share capital Rs m177252 70.1%   
"Free" reserves Rs m11,44224,499 46.7%   
Net worth Rs m11,72124,553 47.7%   
Long term debt Rs m1493,517 4.2%   
Total assets Rs m14,81439,595 37.4%  
Interest coverage x112.912.2 923.8%   
Debt to equity ratio x00.1 8.9%  
Sales to assets ratio x1.20.8 143.8%   
Return on assets %27.45.7 478.6%  
Return on equity %34.28.3 414.6%  
Return on capital %46.510.5 443.7%  
Exports to sales %55.148.6 113.4%   
Imports to sales %6.014.2 42.2%   
Exports (fob) Rs m9,52715,617 61.0%   
Imports (cif) Rs m1,0384,571 22.7%   
Fx inflow Rs m10,42215,617 66.7%   
Fx outflow Rs m1,6785,828 28.8%   
Net fx Rs m8,7449,790 89.3%   
CASH FLOW
From Operations Rs m3,2642,764 118.1%  
From Investments Rs m-2,093-1,432 146.2%  
From Financial Activity Rs m-1,186-1,591 74.5%  
Net Cashflow Rs m-15-259 5.7%  

Share Holding

Indian Promoters % 73.8 45.9 160.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 1.6 11.4 13.6%  
FIIs % 7.6 25.3 30.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.0 17.4 97.7%  
Shareholders   20,968 36,892 56.8%  
Pledged promoter(s) holding % 4.4 2.1 205.1%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   DR. REDDYS LAB  PIRAMAL ENTERPRISES  NATCO PHARMA  SUN PHARMA  PFIZER  

Compare AJANTA PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes Marginally Lower; Capital Goods & Realty Stocks Fall(Closing)

Indian share markets witnessed selling pressure in the final hour of trade to finish just below the dotted line. At the closing bell, the BSE Sensex closed lower by 71 points.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Follow India's Super Investors to Make Big Money in the Market Crash(The 5 Minute Wrapup)

Feb 8, 2018

Has the sell-off in the markets left India's super investors unduly worried?

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

Rising Dominance of Mutual Funds(Chart Of The Day)

Feb 8, 2018

Domestic money flow into Indian equities surpassed foreign fund flows in the recent years. But will it continue in volatile market?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Feb 20, 2018 (Close)

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA 8-QTR ANALYSIS

COMPARE AJANTA PHARMA WITH

MARKET STATS